search for




 

A Mini Overview of Isolation, Characterization and Application of Amniotic Fluid Stem Cells
International Journal of Stem Cells 2015;8:115-120
Published online November 30, 2015;  
© 2015 Korean Society for Stem Cell Research.

Shiva Gholizadeh-Ghalehaziz1, Raheleh Farahzadi2, Ezzatollah Fathi3, and Maryam Pashaiasl4

1Department of Molecular Medicine, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran, 2Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, 3Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Iran, 4Department of Reproductive Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Correspondence to: Ezzatollah Fathi, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, 29 Bahman Street, Jamejam Avenue, Tabriz 5166616471, Iran, Tel: +98-4133392351, Fax: +98-4133392351, E-mail: ez.fathi@tabrizu.ac.ir
; Accepted August 31, 2015.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Amniotic fluid represents rich sources of stem cells that can be used in treatments for a wide range of diseases. Amniotic fluid- stem cells have properties intermediate between embryonic and adult mesenchymal stem cells which make them particularly attractive for cellular regeneration and tissue engineering. Furthermore, scientists are interested in these cells because they come from the amniotic fluid that is routinely discarded after birth. In this review we give a brief introduction of amniotic fluid followed by a description of the cells present within this fluid and aim to summarize the all existing isolation methods, culturing, characterization and application of these cells. Finally, we elaborate on the differentiation and potential for these cells to promote regeneration of various tissue defects, including fetal tissue, the nervous system, heart, lungs, kidneys, bones, and cartilage in the form of table.

Keywords : Amniotic fluid, Amniotic fluid- stem cells, Isolation, Differentiation, Tissue engineering
Introduction

The aim of regenerative medicine is currently underway to use the body’s own cells to repair diseased or damaged tissue. The use of stem cells from different tissues for regenerative medicine applications has increased over the past few years. Amniotic fluid (AF) represents rich sources of stem cells population deriving from either the fetus or the surrounding amniotic membrane that can be used for clinical therapeutic applications in the patients who develop organ failure that have resistance to current therapies. The AF was first studied at the beginning of the 20th century (1). Initial studies have been performed in order to detect fetal abnormalities during development the fetus (2). Isolation and identification of amniotic fluid- stem cells (AFSCs) dating back to the early 1990’s (3). The study of AFSCs has received significant attention of late for several reasons. First, AF is easily collected during the first trimester of pregnancy by scheduled amniocenteses for fetal karyotyping, prenatal diagnosis and detection a variety of genetic diseases (4). Second, expansion and storage of AFSCs is easy and achieved at minimal costs. Finally, these cells could be stored in cell banks and used in disease research, drug screening and genetic disorders.

Amniotic Fluid

Human AF is a protective and nourishing watery liquid that providing mechanical support during embryogenesis and is constituted of about 98% water (4). Other ingredients include electrolytes, pigments, sugars, fats, amino acids, proteins, carbohydrates, enzymes, growth factors and cells (5). This volume and composition varies throughout pregnancy (5, 6). After formation of the amniotic cavity, 7~8 days after fertilization, this fluid starts to gather immediately. AF volume increases progressively and is then completely surrounding the embryo after 4 weeks of pregnancy. The average volume is 270 ml at week 16 which increases to 400 ml at week 20 of pregnancy and 800 ml at birth (5). At the beginning of pregnancy, the amniotic osmolarity is similar to the fetal plasma. After keratinization of the fetal skin, which usually occurs at week 24 of pregnancy, amniotic osmolarity decreases relatively to maternal or fetal plasma, mainly due to the inflow of fetal urine (7). Additional investigations have been recently focused on the cellular and molecular properties of amniotic derived cells and their potential use in pre-clinical models and in cell therapies (4).

Isolation and culturing of AFSCs

There are three major protocols for isolation of AFSCs from human amniotic fluid. The first one is based on single-stage method (8). In this method AF collected from second-trimester amniocentesis is centrifuged. The number of cells is counted by hemocytometer and mixed with an equal volume of culture medium, usually Dulbecco’s Modified Eagle Medium (DMEM) supplemented with Fetal Bovine Serum (FBS) and the cells allowed to adhere to a plastic culture plate at 104 cells/cm2 and incubated overnight at 37°C under 5% CO2 (9). Culture medium is changed after 3~5 days to remove non adherent cells and twice weekly thereafter. The primary cells are cultured for 4~5 days until they reached confluence and are defined as passage “0”. In this step the heterogeneous morphological cell population appears and after several sub-culturing the fibroblastic like cells was dominated. The cells typically reach confluence in 4 to 6 days and the remaining cells are cryopreserved in cryopreservation media (10% dimethylsulfoxide, 90% FBS), frozen at ?80°C for 24 h, and stored in liquid nitrogen the next day. The second one is immunoselection based on surface antigens. Ditadi was the first researcher to show that the c-Kit population cells extracted from the AF do have hematopoietic potential (10). At this time, Atala et al. (2) and Schmidt et al. (11) isolated CD117 positive cells by c-kit (a rabbit polyclonal antibody to CD117) and CD133 positive cells by CD133 magnetic beads, respectively. Their study showed these cells can be easily expanded in cultures and sub-population of CD133 positive exhibited similar characteristics of mesenchymal progenitors cells (11). Following these studies, Arnhold et al. sorted CD117 positive cells by magnetic associated cell sorting. They indicated that the percentage of CD117 positive cells was 3.2±1.03% of the whole cell population and demonstrated that these cells could differentiate to adipogenic, osteogenic, myogenic and neurogenic lineage (12). The third one is the two-stage culture protocol established by Tsai et al., using nonadhering AF cells of the primary amniocytes culture to isolate AFSCs. In this protocol, nonadhering AF cells are collected from supernatant of AFCs that cultured in serum-free changes medium (first stage). Then collected cells are plated for AFSCs culturing after the completion of fetal chromosome analysis (second stage) (13). This method has some advantages over the others. Major advantage of this culture protocol comparing to the other two is that instead of the adhering cells derived in AF it isolates from the nonadhering cells, which is being left in the incubator without any added nutrition for 7~10 days (13). As mentioned two-stage method is more superior compared to other methods, the use of this method have been proposed.

Characterization and application of AFSCs

The AFSCs are mainly composed of three heterogeneous groups of adherent cells, calcified based on their growth, morphological and biochemical characteristics that derived from the three germ layers (14). Epithelioid (E-type) cells that are cuboidal to columnar, derived from the fetal skin and urine, AF (AF-type) cells are originating from fetal membranes, and fibroblastic (F-type) cells are generated mainly from fibrous connective tissue. The percentage of these cells is 33.7%, 60.8% and 5.5%. Some studies have reported that AFSCs can be easily obtained from a small amount of AF (4, 15). Like other mesenchymal stem cells (MSCs), the AFSCs expressed CD73, CD90, CD105, CD29, CD166, CD49e, CD58, CD44 and HLA-ABC antigens and are negative for the hematopoietic markers such as CD14, CD34, CD45 and CD133, the endothelial marker such as CD31, and the HLA-DR antigen (Fig. 1) (4). These cells are able to differentiate along adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic pathways (Table 1) (16?19). Additionally, the majority of these cells expressed the pluripotency markers such as the octamer binding protein 3/4 (Oct-3/4), the homebox transcription factor Nanog, and the stage-specific embryonic antigen 4 (SSEA-4) (20, 21). Similar to MSCs, AFSCs express MHC II at a very low level. Unlike human MSCs that are telomerase negative, low to moderate levels of the enzyme have been described in AFSCs (5, 22). Telomerase is an enzyme that maintains telomere sequences at chromosomal ends (23). Telomeres consist of TTAGGG repeats protect the ends of chromosomes from end-to-end fusion, recombination and deterioration (5). The presence of telomerase activity in both cultured and uncultured cells was found in 1999 (24). Another interesting finding have shown the presence of a population of Oct-4-positive cells in AF (25). AFSCs also express vimentin and alkaline phosphatase, which are markers of pluripotent stem cells (5, 26). Like other MSCs, AFSCs are attractive candidates for clinical applications, which were reviewed in Table 2. For instance some reports indicated that the AF can be a reliable and practical source of cells for the engineering of select fetal tissue constructs (27, 28). Another clinical application of AFSCs is the use as produce mineralized bioengineered constructs in vivo, functional repair of bone defects and bone engineering (2, 29?31), Neural tissue regeneration and nerve myelination (32?35), lung epithelial regeneration (36, 37), cardiac regeneration (38, 39) and kidney regeneration (21).

Conclusion

Like other MSCs, AFSCs have advantages such as rapid cell proliferation, low or negligible immunogenicity. Many of these cells seem to express some of the same pluripotency markers. All of these features make them valuable for potential therapy applications. Thus far they have been used in pre-clinical settings to treat a variety of diseases such as osteogenesis imperfecta, congenital diaphragmatic hernia, Parkinson’s disease and cancer with encouraging results. Finally, their usefulness for AFSCs is very likely to expand their future clinical use even further. Human AFSCs could be isolated by several methods including immunoselection method based on surface antigens, single-stage and two-stage methods. Two-stage method has some advantages over the others. For example this method doesn’t interfere with the normal culture process for fetal karyotyping and also illustrated their ability to successfully differentiate into osteocyte, adipocyte and etc in vitro. As two-stage method is more superior compared to other methods, the use of this method have been proposed.

Figures
Fig. 1. Diagram for AFSCs characterization.
TABLES

Some researches on differentiation potential of AFSCS

Author namesYear of publicationTitle of publicationType of differentiationMain results
McLaughlin et al.2006Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human AFSCsNeural dupaminergic differentiationThey reported that AFSCs1 are primarily composed of a population of progenitors with a phenotype similar to that of committed dopaminergic neurons (18)
Perin et al.2007Renal differentiation of AFSCsRenal differentiationAFSCs may represent a potentially limitless source of ethically neutral, unmodified pluripotential cells for kidney regeneration (19)
Carraro et al.2008Human AFSCs can integrate and differentiate into epithelial lung lineagesEpithelial lung lineages differentiationHuman AFSCs can undergo lung-specific line-age differentiation and that these cells possess a certain level of plasticity in response to different types of lung damage (36)
Donaldson et al.2009Human AFSCs do not differentiate into dopamine neurons in vitro or after transplantation in vivoNeural dupaminergic differentiationAFSCs express specific markers of neural progenitors and immature dopamine neurons, but were unable to fully differentiate into dopamine neurons in vitro or in vivo (17)
Ditadi et al.2010Human and murine AF2cKit+Lin-cells display hematopoietic activityErythroid, myeloid, and lymphoid lineagesUnder appropriate differentiation conditions, AFSCs were able to generate all the blood lineages (myeloid, erythroid and lymphoid colonies) (10)
Hauser et al.2010Stem cells derived from human AF contribute to acute kidney injury recoveryRenal differentiationThey reported that hAFSCs may provide an alternative source of stem cells for the treatment of acute kidney injury (16)
Peister et al.2011Cell sourcing for bone tissue engineering: AFSCs have a delayed, robust differentiation compared to MSCsOsteogenic differentiationStem cell source can dramatically influence the magnitude and rate of osteogenic differentiation in vitro (27)

1 Amniotic fluid stem cells,

2 Amniotic fluid.


Some researches on application of AFSCs

Author namesYear of publicationTitle of publicationApplicationMain results
Kaviani et al.2001The AF3 as a source of cells for fetal tissue engineeringFetal tissue reconstructionThey seeded subpopulation of MSCs4 from the AF onto a polyglycolic acid polymer/poly-4-hydroxybutyrate scaffold and reported that these cells were able to attach firmly to the scaffolds and form confluent layers with no evidence of cell (23)
Kunisaki et al.2006Fetal cartilage engineering from amniotic mesenchymal progenitor cellsTissue engineeringAF could be a good cell source for tissue engineered diaphragmatic reconstruction (24)
De Coppi et al.2007Isolation of amniotic stem cell lines with potential for therapyBone mineralizationImplantation of AFSCs5 into an immunodeficient mouse cause to production of mineralized tissue in vivo (2)
Cipriani et al.2007Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brainRegeneration of neural tissueCipriani et al. noticed AFSCs grafted cells tended to migrate towards injured brain regions and differentiated into neurons. They suggested the amniotic fluid could be an alternative source for MSCs (28)
Pan et al.2007Post-injury regeneration in rat sciatic nerve facilitated by neurotrophic factors secreted by AF MSCsRegeneration sciatic nerveAFSCs could increase nerve degeneration due to the neurotrophic factors secretion (29)
Carraro et al.2008Human AFSCs can integrate and differentiate into epithelial lung lineagesLung epithelial regenerationAFSCs transplantation into an injured lung cause to pulmonary lineage differentiation (32)
Chenge et al.2010Enhancement of regeneration with glia cell line-derived neurotrophic factor-transduced human AF MSCs after sciatic nerve crush injuryPeripheral nerve regenerationThey embedded AFSCs and glial cells in matrigel and transplanted in to the injured sciatic nerve of rat and indicated that AFSCs promoted nerve regeneration (30)
Pan et al.2009Combination of G-CSF6 administration and human AF MSCs transplantation promotes peripheral nerve regenerationPeripheral nerve regenerationThey embedded AFSCs in fibrin glue and delivered to the injured sciatic nerve. Increased nerve myelination and improved motor function were observed in AFS transplanted (31)
Yeh et al.2010Cellular cardiomyoplasty with human AFSCs: in vitro and in vivo studiesCellular car diomyoplastyAFSCs induce angiogenesis at the injured site, have cardiomyogenic potential, and may be used as a new cell source for cellular cardiomyoplasty (34)
Yeh et al.2010Cardiac repair with injectable cell sheet fragments of human AFSCs in an immune-suppressed rat modelCardiac regenerationTransplantation of AFSCs sheet fragments stimulated a significant increase in vascular density, improved wall thickness and a reduction in the infarct size (35)
Peterson et al.2010Tissue-engineered lungs for in vivo implantationLung regenerationThe results suggested that repopulation of lung matrix is a viable strategy for lung regeneration (33)
Perin et al.2010Protective effect of human AFSCs in an immunodeficient mouse model of acute tubular necrosisKidney regenerationThey found that injection of AFSCs into damaged kidney modulate the kidney immune milieu in renal failure (17)
Rosa et al.2010MSCs lead to bone differentiation when cocultured with dental pulp stemBone engineeringCombination of AFSCs with dental pulp stem cells may provide a rich source of soluble proteins useful for bone engineering purposes (25)
Maraldi et al.2011Human AFSCs seeded in fibroin scaffold produce in vivo mineralized matrixBone engineeringThe results indicated the strong potential of AFSCs to produce mineralized bioengineered constructs in vivo (26)
Peister et al.2011Cell sourcing for bone tissue engineering: AFSCs have a delayed, robust differentiation compared to MSCsBone regenerationThey investigated the cells were cultured within the porous medical grade poly-epsiloncaprolactone (mPCL) scaffolds could differentiate to osteoblastic cells and concluded that the AFSCs were an effective source for functional repair of bone defects (27)

3 Amniotic fluid,

4 Mesenchymal stem cells,

5 Amniotic fluid stem cells,

6 Granulocyte colony-stimulating factor.


References
  1. Underwood, MA, Gilbert, WM, and Sherman, MP (2005). Amniotic fluid: not just fetal urine anymore. J Perinatol. 25, 341-348.
    Pubmed CrossRef
  2. De Coppi, P, Bartsch, G, Siddiqui, MM, Xu, T, Santos, CC, Perin, L, Mostoslavsky, G, Serre, AC, Snyder, EY, Yoo, JJ, Furth, ME, Soker, S, and Atala, A (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 25, 100-106.
    Pubmed CrossRef
  3. Perin, L, Sedrakyan, S, Da Sacco, S, and De Filippo, R (2008). Characterization of human amniotic fluid stem cells and their pluripotential capability. Methods Cell Biol. 86, 85-99.
    Pubmed CrossRef
  4. Roubelakis, MG, Trohatou, O, and Anagnou, NP (2012). Amniotic fluid and amniotic membrane stem cells: marker discovery. Stem Cells Int. 2012, 107836.
    Pubmed KoreaMed CrossRef
  5. Eslaminejad, MB, and Jahangir, S (2012). Amniotic fluid stem cells and their application in cell-based tissue regeneration. Int J Fertil Steril. 6, 147-156.
  6. Cananzi, M, Atala, A, and De Coppi, P (2009). Stem cells derived from amniotic fluid: new potentials in regenerative medicine. Reprod Biomed Online. 18, 17-27.
    Pubmed CrossRef
  7. Ghionzoli, M, Cananzi, M, Zani, A, Rossi, CA, Leon, FF, Pierro, A, Eaton, S, and De Coppi, P (2010). Amniotic fluid stem cell migration after intraperitoneal injection in pup rats: implication for therapy. Pediatr Surg Int. 26, 79-84.
    CrossRef
  8. Steigman, SA, and Fauza, DO (2007). Isolation of mesenchymal stem cells from amniotic fluid and placenta. Curr Protoc Stem Cell Biol. Chapter 1, .
    CrossRef
  9. In ‘t Anker, PS, Scherjon, SA, Kleijburg-van der Keur, C, de Groot-Swings, GM, Claas, FH, Fibbe, WE, and Kanhai, HH (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 22, 1338-1345.
    CrossRef
  10. Ditadi, A, de Coppi, P, Picone, O, Gautreau, L, Smati, R, Six, E, Bonhomme, D, Ezine, S, Frydman, R, Cavazzana-Calvo, M, and Andr?-Schmutz, I (2009). Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. Blood. 113, 3953-3960.
    Pubmed CrossRef
  11. Schmidt, D, Achermann, J, Odermatt, B, Breymann, C, Mol, A, Genoni, M, Zund, G, and Hoerstrup, SP (2007). Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation. 116, I64-I70.
    Pubmed CrossRef
  12. Cananzi, M, and De Coppi, P (2012). CD117(+) amniotic fluid stem cells: state of the art and future perspectives. Organogenesis. 8, 77-88.
    Pubmed KoreaMed CrossRef
  13. Tsai, MS, Lee, JL, Chang, YJ, and Hwang, SM (2004). Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 19, 1450-1456.
    Pubmed CrossRef
  14. Roubelakis, MG, Pappa, KI, Bitsika, V, Zagoura, D, Vlahou, A, Papadaki, HA, Antsaklis, A, and Anagnou, NP (2007). Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev. 16, 931-952.
    Pubmed CrossRef
  15. Roubelakis, MG, Bitsika, V, Zagoura, D, Trohatou, O, Pappa, KI, Makridakis, M, Antsaklis, A, Vlahou, A, and Anagnou, NP (2011). In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med. 15, 1896-1913.
    CrossRef
  16. Hauser, PV, De Fazio, R, Bruno, S, Sdei, S, Grange, C, Bussolati, B, Benedetto, C, and Camussi, G (2010). Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. Am J Pathol. 177, 2011-2021.
    Pubmed KoreaMed CrossRef
  17. Donaldson, AE, Cai, J, Yang, M, and Iacovitti, L (2009). Human amniotic fluid stem cells do not differentiate into dopamine neurons in vitro or after transplantation in vivo. Stem Cells Dev. 18, 1003-1012.
    CrossRef
  18. McLaughlin, D, Tsirimonaki, E, Vallianatos, G, Sakellaridis, N, Chatzistamatiou, T, Stavropoulos-Gioka, C, Tsezou, A, Messinis, I, and Mangoura, D (2006). Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human amniotic fluid cells. J Neurosci Res. 83, 1190-1200.
    Pubmed CrossRef
  19. Perin, L, Giuliani, S, Jin, D, Sedrakyan, S, Carraro, G, Habibian, R, Warburton, D, Atala, A, and De Filippo, RE (2007). Renal differentiation of amniotic fluid stem cells. Cell Prolif. 40, 936-948.
    Pubmed CrossRef
  20. Klemmt, PA, Vafaizadeh, V, and Groner, B (2011). The potential of amniotic fluid stem cells for cellular therapy and tissue engineering. Expert Opin Biol Ther. 11, 1297-1314.
    Pubmed CrossRef
  21. Perin, L, Sedrakyan, S, Giuliani, S, Da Sacco, S, Carraro, G, Shiri, L, Lemley, KV, Rosol, M, Wu, S, Atala, A, Warburton, D, and De Filippo, RE (2010). Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. PLoS One. 5, e9357.
    Pubmed KoreaMed CrossRef
  22. Zimmermann, S, Voss, M, Kaiser, S, Kapp, U, Waller, CF, and Martens, UM (2003). Lack of telomerase activity in human mesenchymal stem cells. Leukemia. 17, 1146-1149.
    Pubmed CrossRef
  23. Karlmark, KR, Freilinger, A, Marton, E, Rosner, M, Lubec, G, and Hengstschl?ger, M (2005). Activation of ectopic Oct-4 and Rex-1 promoters in human amniotic fluid cells. Int J Mol Med. 16, 987-992.
    Pubmed
  24. Kim, J, Lee, Y, Kim, H, Hwang, KJ, Kwon, HC, Kim, SK, Cho, DJ, Kang, SG, and You, J (2007). Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif. 40, 75-90.
    Pubmed CrossRef
  25. DiGiulio, DB, Romero, R, Amogan, HP, Kusanovic, JP, Bik, EM, Gotsch, F, Kim, CJ, Erez, O, Edwin, S, and Relman, DA (2008). Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One. 3, e3056.
    Pubmed KoreaMed CrossRef
  26. Prusa, AR, Marton, E, Rosner, M, Bernaschek, G, and Hengstschl?ger, M (2003). Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research?. Hum Reprod. 18, 1489-1493.
    Pubmed CrossRef
  27. Kaviani, A, Perry, TE, Dzakovic, A, Jennings, RW, Ziegler, MM, and Fauza, DO (2001). The amniotic fluid as a source of cells for fetal tissue engineering. J Pediatr Surg. 36, 1662-1665.
    Pubmed CrossRef
  28. Kunisaki, SM, Jennings, RW, and Fauza, DO (2006). Fetal cartilage engineering from amniotic mesenchymal progenitor cells. Stem Cells Dev. 15, 245-253.
    Pubmed CrossRef
  29. De Rosa, A, Tirino, V, Paino, F, Tartaglione, A, Mitsiadis, T, Feki, A, d’Aquino, R, Laino, L, Colacurci, N, and Papaccio, G (2011). Amniotic fluid-derived mesenchymal stem cells lead to bone differentiation when cocultured with dental pulp stem cells. Tissue Eng Part A. 17, 645-653.
    CrossRef
  30. Maraldi, T, Riccio, M, Resca, E, Pisciotta, A, La Sala, GB, Ferrari, A, Bruzzesi, G, Motta, A, Migliaresi, C, Marzona, L, and De Pol, A (2011). Human amniotic fluid stem cells seeded in fibroin scaffold produce in vivo mineralized matrix. Tissue Eng Part A. 17, 2833-2843.
    Pubmed CrossRef
  31. Peister, A, Woodruff, MA, Prince, JJ, Gray, DP, Hutmacher, DW, and Guldberg, RE (2011). Cell sourcing for bone tissue engineering: amniotic fluid stem cells have a delayed, robust differentiation compared to mesenchymal stem cells. Stem Cell Res. 7, 17-27.
    Pubmed KoreaMed CrossRef
  32. Cipriani, S, Bonini, D, Marchina, E, Balgkouranidou, I, Caimi, L, Grassi Zucconi, G, and Barlati, S (2007). Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brain. Cell Biol Int. 31, 845-850.
    Pubmed CrossRef
  33. Pan, HC, Cheng, FC, Chen, CJ, Lai, SZ, Lee, CW, Yang, DY, Chang, MH, and Ho, SP (2007). Post-injury regeneration in rat sciatic nerve facilitated by neurotrophic factors secreted by amniotic fluid mesenchymal stem cells. J Clin Neurosci. 14, 1089-1098.
    Pubmed CrossRef
  34. Cheng, FC, Tai, MH, Sheu, ML, Chen, CJ, Yang, DY, Su, HL, Ho, SP, Lai, SZ, and Pan, HC (2010). Enhancement of regeneration with glia cell line-derived neurotrophic factor-transduced human amniotic fluid mesenchymal stem cells after sciatic nerve crush injury. J Neurosurg. 112, 868-879.
    CrossRef
  35. Pan, HC, Chen, CJ, Cheng, FC, Ho, SP, Liu, MJ, Hwang, SM, Chang, MH, and Wang, YC (2009). Combination of G-CSF administration and human amniotic fluid mesenchymal stem cell transplantation promotes peripheral nerve regeneration. Neurochem Res. 34, 518-527.
    CrossRef
  36. Carraro, G, Perin, L, Sedrakyan, S, Giuliani, S, Tiozzo, C, Lee, J, Turcatel, G, De Langhe, SP, Driscoll, B, Bellusci, S, Minoo, P, Atala, A, De Filippo, RE, and Warburton, D (2008). Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells. 26, 2902-2911.
    Pubmed KoreaMed CrossRef
  37. Petersen, TH, Calle, EA, Zhao, L, Lee, EJ, Gui, L, Raredon, MB, Gavrilov, K, Yi, T, Zhuang, ZW, Breuer, C, Herzog, E, and Niklason, LE (2010). Tissue-engineered lungs for in vivo implantation. Science. 329, 538-541.
    Pubmed KoreaMed CrossRef
  38. Yeh, YC, Wei, HJ, Lee, WY, Yu, CL, Chang, Y, Hsu, LW, Chung, MF, Tsai, MS, Hwang, SM, and Sung, HW (2010). Cellular cardiomyoplasty with human amniotic fluid stem cells: in vitro and in vivo studies. Tissue Eng Part A. 16, 1925-1936.
    Pubmed CrossRef
  39. Yeh, YC, Lee, WY, Yu, CL, Hwang, SM, Chung, MF, Hsu, LW, Chang, Y, Lin, WW, Tsai, MS, Wei, HJ, and Sung, HW (2010). Cardiac repair with injectable cell sheet fragments of human amniotic fluid stem cells in an immune-suppressed rat model. Biomaterials. 31, 6444-6453.
    Pubmed CrossRef


October 2018, 11 (2)